🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 20 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/05/2018 16,00 16,36 15,31 15,69 -2,00% 6,56% 80.600
11/05/2018 16,56 16,88 15,72 16,01 -1,90% 7,00% 220.200
10/05/2018 16,52 16,78 15,75 16,32 -3,09% 6,21% 239.900
09/05/2018 15,92 17,20 15,76 16,84 +6,18% 9,08% 74.500
08/05/2018 16,35 16,45 15,53 15,86 -3,12% 5,66% 124.800
07/05/2018 17,30 17,36 16,20 16,37 -3,99% 6,71% 79.100
04/05/2018 16,20 17,28 16,20 17,05 +4,60% 6,70% 68.500
03/05/2018 15,60 16,46 15,56 16,30 +3,95% 5,78% 132.900
02/05/2018 14,94 16,00 14,94 15,68 +3,91% 7,10% 51.500
01/05/2018 15,05 15,46 14,66 15,09 -0,85% 5,32% 136.300
30/04/2018 15,22 15,49 14,87 15,22 -0,78% 4,07% 48.100
27/04/2018 15,47 15,78 15,00 15,34 -1,92% 5,01% 201.100
26/04/2018 15,37 15,72 15,00 15,64 +1,03% 4,65% 63.400
25/04/2018 15,26 15,50 14,47 15,48 +0,58% 6,75% 117.800
24/04/2018 16,02 16,11 14,78 15,39 -3,81% 8,30% 209.300
23/04/2018 16,25 16,99 15,75 16,00 -1,84% 7,60% 104.000
20/04/2018 16,02 16,39 15,79 16,30 +0,93% 3,75% 152.500
19/04/2018 16,15 16,36 15,40 16,15 -1,52% 5,94% 210.200
18/04/2018 17,00 17,60 16,03 16,40 -3,24% 9,25% 158.900
17/04/2018 16,74 17,25 16,03 16,95 +1,44% 7,32% 77.300
16/04/2018 15,30 16,80 14,77 16,71 +9,43% 13,29% 213.500
13/04/2018 14,96 15,64 14,77 15,27 +2,48% 5,85% 124.100
12/04/2018 14,76 15,10 14,38 14,90 +0,34% 4,91% 81.900
11/04/2018 13,50 15,00 13,26 14,85 +9,59% 12,89% 404.400
10/04/2018 13,69 14,14 13,27 13,55 -1,02% 6,36% 398.600
09/04/2018 14,50 14,52 13,30 13,69 -4,53% 8,37% 254.000
06/04/2018 14,81 14,85 14,14 14,34 -4,72% 4,79% 1.017.200
05/04/2018 15,68 15,73 14,62 15,05 -3,83% 7,12% 100.900
04/04/2018 15,55 15,86 15,31 15,65 +0,26% 3,54% 139.400
03/04/2018 15,90 16,08 15,43 15,61 -1,76% 4,11% 100.400